ClearPoint Neuro Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue grew 36% YoY to $12.1M, led by navigation and equipment, while gross margin fell to 58%. $22M of ATM proceeds funded expansion; mid-teens 2027 base growth is an early view, with regulatory and trial milestones key.
-
Q2 2026 revenue grew 18% year-over-year to $10.9M, with strong gains in navigation and capital equipment segments, but a decline in biologics due to a non-recurring order. Strategic focus shifted to clinical support, CAL facility ramp, and technology development, with 2026 revenue guidance set at $48–$52M and high-teen to 20% growth expected for 2027.
-
Record Q1 2026 revenue of $12.1M (43% growth) driven by organic and IRRAflow contributions, with gross margin up to 64%. 2026 revenue is guided at $52–$56M, all segments expected to grow double digits, and integration synergies are improving margins and global reach.
Fiscal Year 2025
-
2025 saw record revenue growth, a successful IRRAS acquisition, and strong momentum into 2026, with all core segments expected to grow double digits. Guidance for 2026 is $52M–$56M, reflecting FDA and integration factors, and long-term targets remain ambitious.
-
Q3 2025 revenue grew 9% year-over-year to $8.9 million, with gross margin rising to 63%. The company announced a merger with IRRAS, expanding its neurocritical care portfolio and commercial scale, and expects combined 2026 revenue of $54–60 million.
-
Q2 2025 revenue grew 17% year-over-year to $9.2M, driven by strong performance across all segments and record adoption of new products. Cash position strengthened to $41.5M, supporting global expansion and ongoing investments in cell and gene therapy delivery.
-
Q1 2025 revenue grew 11% year-over-year to $8.5M, led by strong gains in neurosurgery navigation and biologics. New funding from Oberland Capital ensures multi-year strategic flexibility, while new product launches and a shift to subscription models position the company for accelerated growth.
Fiscal Year 2024
-
Revenue grew 31% in 2024 to $31.4M, with gross margin rising to 61%. The company enters its "Fast Forward" phase, targeting 15–31% revenue growth in 2025, driven by new product launches, expanded global reach, and increasing demand for cell and gene therapy delivery solutions.
-
Q3 2024 saw record revenue of $8.1M, 41% growth, and improved gross margin, with all segments expanding over 20%. Operational cash burn dropped 33%, debt was retired, and guidance remains strong for 2024 and beyond.
-
Record Q2 revenue of $7.9M marked 32% growth year-over-year, with gross margin rising to 63%. Guidance for 2024 revenue was raised to $30–33M, reflecting strong performance across all growth pillars and a robust cash position of $32.8M.